ZEISS launches EVA NEXUS cataract configuration
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 27, 2026
The launch of a new cataract surgical system is expected to strengthen Carl Zeiss Meditec's position in the ophthalmic surgical market, potentially boosting revenue in the medical technology segment. The product debut at a major industry congress may generate positive attention from surgeons and investors, though the financial impact is likely modest in the near term.
Carl Zeiss Meditec announced the availability of the DORC EVA NEXUS ophthalmic surgical system in a dedicated cataract-only configuration. The system, which expands the trusted DORC EVA NEXUS technology, is designed to offer cataract surgeons streamlined performance, stability, and control in the operating room. It will make its global debut at the European Society of Cataract and Refractive Surgeons (ESCRS) congress in London. The cataract configuration features a cataract grade selection with up to four programmable pre-sets, integration with the ZEISS Cataract Workflow, and advanced technologies including VacuFlow VTi, SMART IOP, and EVA EQUIPHACO. Availability begins in select European countries in September 2026, with global availability pending regulatory approvals. The announcement was made by ZEISS Medical Technology, a business of Carl Zeiss Meditec AG, which is listed on the TecDAX and SDAX.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard